New Sanofi study is yet another win for blockbuster drug
![Photo: Thibault Camus/AP/Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13392693.ece/ALTERNATES/schema-16_9/20346347585422-1920x1079we.jpg)
Sanofi is working to expand the indications for its blockbuster drug Dupixent. The firm's latest attempt looks to be a success, as a phase III study generated positive results within skin disease prurigo nodularis.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Sanofi's eczema drug is four-time blockbuster
For subscribers
CHMP recommends six new drugs
For subscribers